welcome
Reuters

Reuters

Health

Health

AstraZeneca to buy EsoBiotec for up to $1 billion

Reuters
Summary
Nutrition label

83% Informative

AstraZeneca has been actively expanding its cell therapy capabilities.

EsoBiotec has technology that can genetically modify immune cells directly inside the body, allowing for transformative cell therapy treatments in just minutes instead of the current process which can take weeks .

The transaction is expected to close in the second quarter of 2025 .

VR Score

92

Informative language

97

Neutral language

76

Article tone

formal

Language

English

Language complexity

86

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links